PFKM and schizophrenia: Confirmation of this phenomenon is the disruption of bioenergy pathways in the dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia and control subjects in whom a decrease in hexokinase (HXK) and phosphofructokinase (PFK) activity in DLPFC was observed, as well as a decrease in PFK1 mRNA expression.